Arcutis Biotherapeutics

Valuation Analysis

About the Company

Arcutis Biotherapeutics en bref

Arcutis Biotherapeutics (ARQT) is currently trading at 23,29 € with a market capitalization of 2,9 Md €. The 52-week range spans from 11,88 € to 27,54 €; the current price is 15.5% below the yearly high. Year-over-year revenue growth stands at +60.1%.

💰 Dividende

Arcutis Biotherapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Arcutis Biotherapeutics (ARQT) au consensus : Achat Fort. L'objectif de cours moyen est de 30,02 €, soit un potentiel de +28.91% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 28,61 € à 31,21 €.

Arcutis Biotherapeutics : la thèse d'investissement en détail

Arcutis Biotherapeutics (ARQT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 60.1% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 90.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 28.91% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 11.57% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 594.99x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 28.91% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (11.57%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Arcutis Biotherapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.